Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2019 Nov 25;14(11):e0225605. doi: 10.1371/journal.pone.0225605

A Q fever outbreak associated to courier transport of pets

Eva Alonso 1, Domingo Eizaguirre 2, Idoia Lopez-Etxaniz 3, José Ignacio Olaizola 3, Blanca Ocabo 4, Jesús Felix Barandika 5, Isabel Jado 6, Raquel Álvarez-Alonso 5, Ana Hurtado 5, Ana Luisa García-Pérez 5,*
Editor: Abdallah M Samy7
PMCID: PMC6876792  PMID: 31765433

Abstract

On August 3rd, 2017, a Q fever outbreak alert was issued at a courier company that in addition to urgent freight transport offered pet delivery services. The epidemiological investigation set the exposition period between June 1 and August 8. In this period, 180 workers from two operational platforms for parcel distribution located in two provinces of the Basque Country (Bizkaia and Araba) were exposed; 64 filled a questionnaire and provided blood samples for serological testing, resulting in 10 confirmed cases (15.6%) and six (9.4%) probable cases. Nine workers (8 confirmed and 1 probable) showed Q fever symptoms, including pneumonia (five cases), and required medical care services, including one hospital admission. The attack rate was 25% (16/64), being higher among workers that visited the Bizkaia platform. This suggested that the origin of the outbreak was in the Bizkaia platform, where animals in transit waited at a pet holding site until being moved to their destination. Environmental samples consisting on 19 surface dust and two aerosol samples were collected at the Bizkaia platform to investigate the presence of C. burnetti DNA. All dust samples were positive by real time PCR, the lowest Ct values being found in dust collected at the pet holding facilities, and therefore suggesting that contamination originated at the pet holding site. The genotype identified in dust was SNP1/MST13, one of the most commonly identified genotypes in goats and sheep in the Basque Country. During the exposure period, two deliveries of miniature goats were made, of which only one could be investigated and tested negative. Although the contamination source could not be unequivocally identified, transport of ruminants was banned at the company, and Q fever was included among the occupational-associated health risks.

Introduction

The intracellular bacterium Coxiella burnetii is the causative agent of Q fever in people and animals. It has been reported that the inhalation of 1 to 10 bacteria can cause disease in people. The most important symptoms are fever, pneumonia and / or hepatitis, though about 60% of infected people are asymptomatic [1]. C. burnetii is worldwide distributed, the only exception being New Zealand [1], and numerous outbreaks of Q fever have been reported. EFSA [2] compiled 39 outbreaks of Q fever in Europe between 1982 and 2007, 32 of them being related to small ruminants. This is due to the fact that Q fever infected farm animals shed millions of bacteria during abortion and parturition through different routes of excretion such as feces, uterine fluids, milk, and placentas [3]. However, pets [1,2], as well as wild species [4], may also carry C. burnetii. In general, outbreaks of human Q fever are related to contact with the animal reservoirs, which maintain the infection active and shed C. burnetii by different routes to the environment. Therefore farmers, veterinarians, shearers or slaughterhouse workers, among others, are those most commonly affected. However, outbreaks occasionally occur in urban nuclei far from the source of infection when weather conditions favor wind transport of C. burnetii [58]. Moreover, C. burnetii can also contaminate materials and be transported from one place to another giving rise to unexpected outbreaks, and making the epidemiological investigation challenging. Environmental sampling proved very useful in tracing back recent outbreaks that occurred in our region at workplaces without apparent contact with animals [9,10]. In addition, the DNA obtained from dust allowed genotyping of the involved isolate and helped to identify the probable source of infection. In this study we present the investigation of an outbreak of Q fever in an express transport company authorized for the transport of pets.

Material and methods

Case presentation

The outbreak occurred in the Basque Country (northern Spain), a region divided into three provinces: Araba, Bizkaia and Gipuzkoa. On August 3, 2017, the Microbiology Laboratory of Hospital Universitario de Cruces (Bizkaia) informed the Epidemiology Surveillance Unit of the province of a possible Q fever outbreak at a courier company located in Bizkaia. The company confirmed that in July several workers of the company branch in Bizkaia were on sick leave. Also in July, another two possible cases of Q fever were reported by the Health Service from a nearby Spanish region (Castilla-León) in two workers of the Araba branch of the same company (60 km away from the Bizkaia platform) who lived in Castilla-León. Since the company was a licensed pet transporter, transported animals were suspected as a possible source of the Q fever outbreak. Under these circumstances, by August 3 the facility where animals were kept had already been cleaned and disinfected, and transport of animals had been suspended.

Courier company description

The outbreak occurred in a courier company that in addition to urgent freight transport of parcels offered pet delivery services. The company is organized in several sections: reception and delivery offices where clients place the parcels; operational platforms for parcel distribution; and, transport services. Only workers at operational platforms are employees of the courier company, whereas reception and delivery offices are franchises and drivers are self-employed.

Pet delivery services offered by the company included transport and delivery of all type of animals, the only restriction being the maximum weight allowed. Pet delivery needs to comply with certain requirements of animal health and welfare. Notably, animals ought to be healthy and health status be accredited by an official health certificate that complies with regulations at origin and destination. Besides, animals cannot be pregnant or not having recently given birth when travelling. Transport routes include delivery to the local platform by the collection site, transfer to the central platform in Madrid, where a veterinarian visually examines the animal, and transport to the local platform at destination. In each platform animals are located in specific pet holding facilities while waiting (less than 1 hour) to be transported. Maximum transit times are 24 hours. About 6–7 animals are delivered each day. Transported animals are mostly dogs and cats, while other animals like miniature sheep and goats, birds or rabbits are delivered once per month on average.

Epidemiological investigation

Once the Epidemiology Surveillance Unit was informed of the suspected Q fever outbreak, a multidisciplinary group that included microbiologists, veterinarians, occupational health technicians and epidemiologists was gathered to investigate the infection source, monitor the exposed workers and design control measures.

On August 9, the Epidemiology Surveillance Unit and the Occupational Health Authority (OSALAN) met with the company management, the doctor and the occupational health technicians to collect information on the outbreak circumstances. The company informed that on July 16 they became aware of several workers from the Bizkaia and Araba branches reporting health problems compatible with Q fever starting on July 4. The following day, July 17, transport of ruminants was suspended at affected branches. That same day, pet holding facilities at the Bizkaia platform were cleaned with soap and bleach by the platform workers, who did not use the necessary protection equipment (eg. respiratory protection masks). Later, on July 22, a specialized cleaning company was subcontracted to clean and disinfect the pet holding facilities at the Bizkaia and Araba platforms, as well as the van used to transport animals. On July 24, transport of ruminants was banned for all transport routes.

Taking into account the incubation period of Q fever infection (2–3 weeks) and the onset date of the clinical signs in the affected patients, the exposure period was defined as that extended between June 1 and August 8. All workers that had any contact with either of the two affected platforms during that period, independently of their contractual relationship with the company, were considered exposed. Two meetings were held, one on each platform, to inform the workers, and conduct an epidemiological questionnaire and a serological study among workers who volunteered to participate. Workers unable attend to the meetings were approached by the Epidemiological Surveillance Unit by phone and asked to complete the questionnaire (S1 Appendix) and those who agreed to also provide blood samples. The workers’ general practitioners (GP) and local hospitals were informed of the outbreak.

Laboratory methods

Serological analyses were carried out at different hospitals and health prevention services. Two blood samples were obtained 3 to 4 weeks apart for serological determination of C. burnetii phase II IgM and IgG antibodies to evaluate seroconversion in exposed workers. Laboratory results were considered positive when seroconversion was observed; laboratory results were considered doubtful when only one blood sample was available and an indirect immunofluorescence antibody test (IFAT) titers for phase II IgG were >1/128 and for phase II IgM of >1/256.

Since ruminants are considered the main source of human Q fever infection in the study area, the investigation of potential infection sources focused on small ruminants that had travelled through either of the affected platforms (Bizkaia and/or Araba) during the exposure period (June 1—August 8). Blood samples (4 mL) were collected from animals to investigate the presence of antibodies against C. burnetii in their blood using a commercial indirect ELISA test (LSIVET Ruminant Milk/Serum Q Fever kit; Thermo Fisher Scientific).

Environmental samples (air and dust) were collected at different locations of the Bizkaia platform on September 15. Two aerosol samples were taken with an air sampler (Airport MD8, Sartorius) inside the platform of Bizkaia. Nineteen surface dust samples were collected using cotton swabs in areas with accumulated dust that included the pet holding facilities and other sites in the company premises. After DNA extraction, samples were analyzed by Real Time PCR (RTi-PCR) [11]. Samples with a positive RTi-PCR result and a Ct value below 31 were genotyped by multispacer sequence typing (MST) and a 10-loci single-nucleotide polymorphism (SNP) discrimination using RTi-PCR as described elsewhere [12,13].

Case definition

A confirmed human case was defined as a worker who had any contact with the Bizkaia and/or Araba platforms of the courier company between June 1 and August 8, 2017, independently of their contractual relationship with the company, and showed seroconversion in laboratory analyses, with or without clinical symptoms (fever, pneumonia and/or hepatitis). Probable cases included those exposed workers with mild clinical symptoms who tested serology positive without seroconversion or produced doubtful laboratory results (see Laboratory methods).

Statistical analyses

Associations between personnel risk factors and data collected in the epidemiological investigation were analyzed by Chi squared test (categorical variables) or by Student's t–test (numerical and dichotomous variables) using SPSS Statistic 21. Attack rates were assessed by Mantel-Haenszel Chi squared test using Epi Info 7 and Odds Ratios were assessed by exact test using Stata 12.1.

Ethical considerations

Since outbreaks are routinely investigated according to the Public Health services’ ethical guidelines to ensure patients safety, this study did not require additional ethical approval. Written informed consent was obtained from the workers for blood sample collection and for filling a questionnaire, which included personal data collection following legal regulations (Ley Orgánica 15/1995). Data analysis was performed on an anonymized dataset.

Blood samples were taken directly from the jugular vein of the goats following Spanish ethical guidelines and animal welfare regulations (Real Decreto 53/2013) after obtaining informed consent from the flock owner. According to this regulation, extraction of blood samples from livestock in this type of studies is considered routine veterinary clinical practice and does not require ethical approval. Samples were collected by the highest authority in animal research, welfare and ethics in the regions, i.e., veterinarians of the local Animal Health and Welfare Authorities (Servicio de Ganadería, Diputación Foral de Bizkaia and Servicio de Sanidad y Producción Animal de Lugo, Xunta de Galicia), responsible of livestock sanitation and studies of zoonotic outbreaks.

Results

Epidemiological investigation

A total of 180 workers from 29 different organizations (including self-employees) were considered to be exposed to the infection and were informed of the outbreak. Of them, 36 lived in other regions and their cases were referred to their local Health Services. Sixty-four of the remaining 144 workers agreed to fill a questionnaire to investigate risk factors of exposure and to provide blood samples for serological testing. Ten of them (15.6%) were identified as confirmed cases and another six (9.4%) met the definition of probable case; the remaining 48 were regarded as non-cases. Nine workers (8 confirmed and 1 probable) showed symptoms compatible with Q fever, including five cases with pneumonia (Table 1). They all required medical care services, including one who needed hospital admission. Another 7 workers had compatible symptoms (including one case of pneumonia) in the outbreak period but none of them met the laboratory criteria of Q fever, and they were thus considered as non-case. The attack rate among the investigated workers was 25% (16/64). Although it was difficult to precisely know if workers visited just one or both of the affected platforms, attack rate at the Bizkaia platform was estimated to be 28.3% (13/46) and 16.7% (3/18) at the Araba platform, all of the latter being asymptomatic. Serological results compiled from workers are shown in S1 Table.

Table 1. Summary of the results obtained in the epidemiological questionnaire according to variables and case definition.

Epidemiological data no. (%)
Confirmed cases (N = 10) Probable cases (N = 6) Non-case (N = 48)
Sex Male 9 (90.0) 6 (100.0) 44 (91.7)
Female 1 (10.0) - 4 (8.3)
Age Mean 45.8 36.5 38.5
Median 45.5 35.0 36.5
Min—Max 33–60 25–54 22–58
Symptoms Any symptom 8 (80.0) 1 (16.7) 7 (14.6) a
Fever / flu-like 8 (80.0) 1 (16.7) 7 (14.6) a
Pneumonia 5 (50.0) - 1 (2.1) a
Medical care Hospitalization 1 (10.0) - -
Emergency services 6 (60.0) - 6 (12.5) a
Primary health care services 1 (10.0) 1 (16.7) 1 (2.2) a
Living in a rural setting 2 (20.0) 1 (16.7) 3 (6.3)
Smoker 9 (90.0) 2 (40.0) 18 (42.9)
Contact with animals (at work) 9 (90.0) 3 (60.0) 36 (75.0)
Working at reception and/or transport services 7 (87.5) 3 (75.0) 26 (59.1)
Involved in cleaning operations 1 (16.7) 1 (33.3) 5 (13.9)

a these workers had compatible symptoms during the exposure period but they did not meet the laboratory criteria of Q fever.

Median and mean age in confirmed cases did not significantly differ from non-affected workers. Percentage of smokers was higher in confirmed and probable cases than in non-cases (p = 0.043). Proportion of workers that had contact with animals at work was higher among confirmed cases, but differences were non-significant (p>0.05). Likewise, attack rate among the personnel involved in cleaning operations was non-significantly higher. No significant differences in incidence were observed between workers living in a rural or urban setting.

The epidemic curve representing the progression of illnesses onset in confirmed and probable cases is shown in Fig 1. First symptoms were recorded on July 5, and extended until August 2, with most cases concentrating during the first two weeks of July; only two cases delayed to August 1 and 2, after cleaning operations at the Bizkaia platform and the ban on animal transport was implemented.

Fig 1. Schematic representation of the main events associated to the outbreak.

Fig 1

Outbreak source investigation: Animal and environmental study findings

Among all animal delivery services carried out between June 1 and August 8, two were considered the most probable sources of the infection. Delivery 1 involved two miniature goats travelling on June 28 from Bizkaia to Orense. Travelling route was as follows: reception at the Bizkaia platform–Araba platform (animals did not leave the van)–central headquarters at Madrid (360 km from Araba platform), where a veterinarian inspected the animals and they were then transferred to a different van–reception office and delivery at Orense. The farm where these miniature goats originated from was inspected by Animal Authority Services. Blood samples were collected from five miniature goats and seven sheep for C. burnetii ELISA test (August 23), all of them being negative. The two suspected miniature goats also tested negative in the ELISA test when investigated at destination (August 25). Delivery 2 took place three weeks before the onset of the outbreak. It also involved the transport of miniature goats but animals only passed through the Bizkaia platform while travelling from Cantabria to Valencia. Since animals did not travel through the Araba platform, and considering the time elapsed since the outbreak and the difficulties associated to the several regions involved, these animals were not investigated.

Being the suspected animal source negative, an environmental study was set up to investigate the presence of C. burnetii at the company premises surrounding the pet holding facilities of the Bizkaia platform, where the higher number of cases occurred. Although by this time the Bizkaia platform had been cleaned and disinfected twice, on September 15, environmental samples (19 surface dust and two aerosols) were collected at different sites of the Bizkaia platform premises. Special attention was paid in collecting samples from sites with accumulated dust and dirt, both inside and outside the pet holding facilities as well as at different surfaces within the company premises (see Fig 2). Real time PCR results were weak positive (Ct>35) for the aerosol samples but all dust samples were positive (Ct≤35), with the lowest Ct values for samples collected at the pet holding facilities (Ct 23.9 and 27.9) (Fig 2). Specifically, the lowest Ct value (23.9) was found for a dust sample collected from the rails of the sliding doors of the pet holding site, where cleaning operations did not reach. These results suggested that contamination had originated there and then spread through the platform premises. The two samples collected at the pet holding site were subjected to genotyping but only one (Ct = 23.9) could be completely genotyped as SNP1 and MST13.

Fig 2. Schematic representation of the Bizkaia platform (2,500 m2) along with the sampling sites and their corresponding C. burnetii Real Time PCR results (Ct values).

Fig 2

Undertaken control measures

As mentioned above, on July 24, transport of ruminants was banned for all transport routes. After the initial cleaning operations at the Araba platform in July, new cleaning and disinfection were performed on August 5 and August 19 using 1% Virkon® S (Bayer Hispania S.L., Barcelona, Spain). At the Bizkaia platform, a third and more stringent cleaning and disinfection procedure was implemented in September 15 upon receipt of the results from the environmental study that confirmed C. burnetii contamination. It involved exhaustive cleaning and disinfection of the pet holding facilities (inside and outside) using wet methods (avoiding any procedures that involved dust formation such as sweeping or aspiration), as well as cleaning and disinfection with water and Virkon® S (Bayer Hispania S.L., Barcelona, Spain) of floors, banisters and any other dust accumulating sites. Differently to the operations in July, now the necessary protection equipment, i.e. respiratory protection masks (filtering face pieces class 3-FFP3), gloves and goggles, were used during cleaning and disinfection.

Prevention Services of the affected companies were asked to follow-up confirmed and probable cases in order to assess possible evolution to chronic Q fever. For self-employees monitoring would be carried out by their GPs.

Discussion

A Q fever outbreak was declared in August 2017 at a courier company. The epidemiological investigation of the outbreak was hampered by the structure of the service that included not only personnel directly employed by the courier company but also workers from franchises and self-employed drivers. This situation hindered the identification of the personnel outside the platforms exposed to the infection source. In addition, workers had their residence in different regions and therefore the collaboration of different Health Services was required. Consequently, not all workers were included in the epidemiological survey. Despite these difficulties, the epidemiological and laboratory studies identified Q fever in 25% of the investigated workers. Pneumonia was the most relevant clinical sign and the cause of hospitalization of one patient. These results support previous studies which also identified pneumonia as the main clinical manifestation associated to other Q fever outbreaks recently reported in the Basque Country [9,10,14], unlike other Spanish regions where hepatitis is the most common clinical presentation [15]. In this sense, the Basque Country has been reported to have the highest rate of Q fever-associated pneumonia in Spain [15,16] and Europe as reviewed elsewhere [17].

Two deliveries of small ruminants (miniature goats) that took place within three weeks prior to the onset of the outbreak were considered as the most probable source of the outbreak. The first one, which took place three weeks before the outbreak (June 15), unfortunately could not be investigated. The second delivery, on June 28, involved the transport of two miniature goats from Bizkaia to Orense passing through both affected platforms. After serological investigation these animals did not show antibodies against C. burnetii, and neither did other animals from their flock of origin. It is nevertheless known that serology is not a good indicator of infection status since a percentage of C. burnetii infected ruminants do not seroconvert [18]. The high values of C. burnetii DNA detected by Real Time PCR on dust samples collected at the pet holding facilities of the Bizkaia platform clearly indicated that contamination originated there. The hypothesis that small ruminants were the infection source was supported by the C. burnetii genotype identified from dust samples (SNP1 / MST13), which corresponds to a type already detected from sheep [19] and goats [14] in the region. Although other pets like cats and dogs can also carry C. burnetii [20], genotype SNP1 / MST13 points at small ruminants as the source. In the study region cats and dogs have never been associated to Q fever outbreaks, but outbreaks were reported elsewhere after cats or dogs gave birth [21,22]. Although cats and dogs cannot be fully ruled out as a possible source of the outbreak, transport of parturient animals is not allowed. Considering all these, the contamination source could not be unequivocally identified. In the case of small ruminants, infected animals are known to shed C. burnetii through feces for several weeks after parturition or abortion [14,23]. Fecal contamination could have been the origin of the spread of high level of bacteria to the environment. Before transport, animals are kept for a while (less than 1h, according to the information provided by the company) in pet holding facilities, a place that workers frequently visited. In fact, about 72.6% of the interviewed workers confirmed direct or indirect contact with the animals at the platforms. Moreover, the air ventilation system of the pet holding facilities expelled air towards the platform. This might have been the main contamination route since C. burnetii DNA was detected all over the platform premises, the lowest PCR Ct values being found at the pet holding facilities. Although detection of C. burnetii DNA in dust samples collected far after the onset of the clinical cases and even after cleaning and disinfection does not prove that the bacteria were viable, it does suggest that contamination originated there. From there, travel containers, transport vans or workers travelling from Bizkaia to Araba could have acted as vehicles for C. burnetii contamination of the Araba platform, where three workers seroconverted but did not show clinical signs of infection. This would explain why attack rate was higher among workers that visited the Bizkaia platform, and those in closer contact with the transported animals.

Until recently, Q fever was considered an occupational disease linked only to the livestock sector. This outbreak highlights the risk of Q fever infection in other working settings where contact with potential animal reservoirs also occurs. Although animal delivery was included among the services offered by the company, Q fever was not considered among the occupational-associated health risks. In fact, even though animals need an official health certificate to travel, the analysis of C. burnetii antibodies is not legally requested, not even for domestic ruminants as occurs for example for Brucella spp. or tuberculosis in sheep and goats. This study highlighted the need to revise policies associated to animal health requirements for transport and consider the inclusion of laboratory tests (serology and PCR) to rule out C. burnetii infection.

This outbreak adds up to other cases and outbreaks where C. burnetii has been accidentally transported to environments far from livestock [5,8,24]. In such cases, outbreak investigations are even greater challenges that need rapid and coordinated One Health approaches. Here, expertise in human, animal and environmental health gathered together to collect epidemiological data and produce laboratory results to investigate the infection source and implement control and prevention measures. Exhaustive cleaning and disinfection procedures were implemented at both affected platforms after the epidemiological outbreak investigation. Transport of ruminants was banned for all transport routes at the company, and Q fever was included among the company occupational-associated health risks.

Supporting information

S1 Appendix. Questionnaire used in the epidemiological investigation.

(DOCX)

S1 Table. Serological data compiled from workers.

(XLSX)

Acknowledgments

We would like to thank all the clinicians and laboratory staff of the Microbiology Services of Osakidetza, the Prevention Services and the Mutual Insurance for Occupational Accidents involved in the management of the outbreak. We are also grateful to the staff of the platform of Bizkaia during the visits and samplings.

Data Availability

All relevant data are within the paper and its Supporting Information files. However, under the Data Protection laws, raw individual personal and clinical data extracted from the questionnaires cannot be provided since they represent sensitive information. However, any request for additional information will be considered and provided upon request to the Epidemiology Service of the Department of Public Health of the Basque Government (e-mail: epidemiologia-bizkaia@euskadi.eus).

Funding Statement

This work was funded by the Spanish National Institute for Agricultural and Food Research and Technology (INIA) (RTA2017-00055-C02-00), the European Regional Development Funds (ERDF) and the Basque Government. RAA is beneficiary of a PhD contract funded by INIA (FPI-2015-014). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

References

  • 1.Eldin C, Melenotte C, Mediannikov O, Ghigo E, Million M, Edouard S et al. From Q fever to Coxiella burnetii infection: a paradigm change. Clin Microbiol Rev. 2017; 30(1): 115–190. 10.1128/CMR.00045-16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.EFSA. Scientific Opinion on Q fever. EFSA J. 2010; 8(5): 1595. [Google Scholar]
  • 3.Rodolakis A, Berri M, Hechard C, Caudron C, Souriau A, Bodier CC et al. Comparison of Coxiella burnetii shedding in milk of dairy bovine, caprine, and ovine herds. J Dairy Sci. 2007; 90(12): 5352–5360. 10.3168/jds.2006-815 [DOI] [PubMed] [Google Scholar]
  • 4.Gonzalez-Barrio D, Ruiz-Fons F. Coxiella burnetii in wild mammals: A systematic review. Transbound Emerg Dis. 2019; 66(2): 662–671. 10.1111/tbed.13085 [DOI] [PubMed] [Google Scholar]
  • 5.Clark NJ, Soares Magalhaes RJ. Airborne geographical dispersal of Q fever from livestock holdings to human communities: a systematic review and critical appraisal of evidence. BMC Infect Dis. 2018; 18(1): 218 10.1186/s12879-018-3135-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Tissot-Dupont H, Torres S, Nezri M, Raoult D. Hyperendemic focus of Q fever related to sheep and wind. Am J Epidemiol. 1999; 150(1): 67–74. 10.1093/oxfordjournals.aje.a009920 [DOI] [PubMed] [Google Scholar]
  • 7.Tissot-Dupont H, Amadei MA, Nezri M, Raoult D. Wind in November, Q fever in December. Emerg Infect Dis. 2004; 10(7): 1264–1269. 10.3201/eid1007.030724 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.van den Brom R, van EE, Roest HI, van der Hoek W, Vellema P. Coxiella burnetii infections in sheep or goats: an opinionated review. Vet Microbiol. 2015; 181(1–2): 119–129. 10.1016/j.vetmic.2015.07.011 [DOI] [PubMed] [Google Scholar]
  • 9.Alonso E, Lopez-Etxaniz I, Hurtado A, Liendo P, Urbaneja F, Aspiritxaga I et al. Q Fever outbreak among workers at a waste-sorting plant. PLoS One. 2015; 10(9): e0138817 10.1371/journal.pone.0138817 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hurtado A, Alonso E, Aspiritxaga I, Lopez E, I, Ocabo B, Barandika JF et al. Environmental sampling coupled with real-time PCR and genotyping to investigate the source of a Q fever outbreak in a work setting. Epidemiol Infect. 2017; 145(9): 1834–1842. 10.1017/S0950268817000796 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Schets FM, de Heer L, de Roda Husman AM. Coxiella burnetii in sewage water at sewage water treatment plants in a Q fever epidemic area. Int J Hyg Environ Health. 2013; 216(6): 698–702. 10.1016/j.ijheh.2012.12.010 [DOI] [PubMed] [Google Scholar]
  • 12.Glazunova O, Roux V, Freylikman O, Sekeyova Z, Fournous G, Tyczka J et al. Coxiella burnetii genotyping. Emerg Infect Dis. 2005; 11(8): 1211–1217. 10.3201/eid1108.041354 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Huijsmans CJ, Schellekens JJ, Wever PC, Toman R, Savelkoul PH, Janse I et al. Single-Nucleotide-Polymorphism genotyping of a Coxiella burnetii during a Q Fever outbreak in The Netherlands. Appl Environ Microbiol. 2011; 77(6): 2051–2057. 10.1128/AEM.02293-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Alvarez-Alonso R, Basterretxea M, Barandika JF, Hurtado A, Idiazabal J, Jado I et al. A Q fever outbreak with a high rate of abortions at a dairy goat farm: Coxiella burnetii shedding, environmental contamination, and viability. Appl Environ Microbiol. 2018; 84(20): e01650–18. 10.1128/AEM.01650-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Alende-Castro V, Macia-Rodriguez C, Novo-Veleiro I, Garcia-Fernandez X, Trevino-Castellano M, Rodriguez-Fernandez S et al. Q fever in Spain: Description of a new series, and systematic review. PLoS Negl Trop Dis. 2018; 12(3): e0006338 10.1371/journal.pntd.0006338 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Perez-Arellano JL, Carranza-Rodriguez C, Gutierrez C, Bolaños M. Epidemiología de la fiebre Q en España (2018). Rev Esp Quimioter. 2018; 31(5): 386–405. [PMC free article] [PubMed] [Google Scholar]
  • 17.Maurin M, Raoult D. Q fever. Clin Microbiol Rev. 1999; 12(4): 518–553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.de Cremoux R, Rousset E, Touratier A, Audusseau G, Nicollet P, Ribaud D et al. Coxiella burnetii vaginal shedding and antibody responses in dairy goat herds in a context of clinical Q fever outbreaks. FEMS Immunol Med Microbiol. 2012; 64(1): 120–122. 10.1111/j.1574-695X.2011.00893.x [DOI] [PubMed] [Google Scholar]
  • 19.Alvarez-Alonso R, Barandika JF, Ruiz-Fons F, Ortega-Araiztegi I, Jado I, Hurtado A et al. Stable levels of Coxiella burnetii prevalence in dairy sheep flocks but changes in genotype distribution after a 10-year period in northern Spain. Acta Vet Scand. 2018; 60(1): 75 10.1186/s13028-018-0429-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Angelakis E, Raoult D. Q fever. Vet Microbiol. 2010; 140(3–4): 297–309. 10.1016/j.vetmic.2009.07.016 [DOI] [PubMed] [Google Scholar]
  • 21.Buhariwalla F, Cann B, Marrie TJ. A dog-related outbreak of Q fever. Clin Infect Dis. 1996; 23(4): 753–755. 10.1093/clinids/23.4.753 [DOI] [PubMed] [Google Scholar]
  • 22.Malo JA, Colbran C, Young M, Vasant B, Jarvinen K, Viney K et al. An outbreak of Q fever associated with parturient cat exposure at an animal refuge and veterinary clinic in southeast Queensland. Aust N Z J Public Health. 2018; 42(5): 451–455. 10.1111/1753-6405.12784 [DOI] [PubMed] [Google Scholar]
  • 23.Astobiza I, Barandika JF, Hurtado A, Juste RA, García-Pérez AL. Kinetics of Coxiella burnetii excretion in a commercial dairy sheep flock after treatment with oxytetracycline. Vet J. 2010; 184(2): 172–175. 10.1016/j.tvjl.2009.01.017 [DOI] [PubMed] [Google Scholar]
  • 24.Georgiev M, Afonso A, Neubauer H, Needham H, Thiery R, Rodolakis A et al. Q fever in humans and farm animals in four European countries, 1982 to 2010. Euro Surveill. 2013; 18(8): pii = 20407 [PubMed] [Google Scholar]

Decision Letter 0

Abdallah M Samy

21 Aug 2019

PONE-D-19-18129

A Q fever outbreak associated to courier transport of pets

PLOS ONE

Dear Dr. García-Pérez,

Thank you very much for submitting your manuscript "A Q fever outbreak associated to courier transport of pets" (#PONE-D-19-18129) for review by PLOS ONE. As with all papers submitted to the journal, your manuscript was fully evaluated by academic editor (myself) and by independent peer reviewers. The reviewers appreciated the attention to an important health topic, but they raised substantial concerns about the paper that must be addressed before this manuscript can be accurately assessed for meeting the PLOS ONE criteria. Therefore, if you feel these issues can be adequately addressed, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We can’t, of course, promise publication at that time.

We would appreciate receiving your revised manuscript by Oct 05 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Abdallah M. Samy, PhD

Academic Editor

PLOS ONE

Additional Editor Comments:

I invited and received three reviews for your manuscript. All reviews raised some substantial concerns about your manuscript as it currently stands. I read through their comments and found that they coincided on several points, and that their reviews were uniformly solid and detailed. I read the manuscript myself, and I must say that I coincide with the reviewers' points entirely. As such, I would recommend “major revision”. I would kindly ask you to go through all comments raised by each reviewer and address them properly before sending a revised version of this manuscript. Please check all PLOS ONE style requirements available via https://journals.plos.org/plosone/s/submission-guidelines before submitting the revised version.

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Methods, please state the volume of the blood samples collected for use in your study."

3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

Reviewer #3: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Although I believe that the authors have investigated the outbreak with care, I do not believe that the article has any new or illuminating insights. It is not at all surprising that an outbreak of Q fever occurred in a business that transported goats and sheep. The association of Q fever with these ruminants was established decades ago, and the ability of Coxiella burnetii to survive in dust for long periods is also well-known. The clinical features of disease in the infected patients in this study are consistent with previous reports, with no novel elements noted.

Reviewer #2: AUTHORS

Manuscript Number: PONE-D-19-18129

Manuscript Title: A Q fever outbreak associated to courier transport of pets

This is an outbreak report of Q fever in an express transport company linked to the transport of caprine, that had epidemic characteristics. It is an interesting and valid text that has an impact on the Public Health approach of this zoonosis. However I have major concerns that need to be addressed before acceptance.

1. Line 78: “possible cases of Q fever in two workers of the Araba branch of the same company who lived in Castilla-León.” What do you mean by Bizkaia and Araba branches? Are these cities? How far apart? How is this connected to Castilla-Leon? I believe this sentence would gain if rephrased for clarification.

2. Line 144: “masks). Later on, on July 22, a specialized” delete “on”

3. No environmental samples were taken from Araba and no link was found between these two branches that could justify a common cause (for example, same animal provider), other than occurring on the same dates. Additionally, molecular evidence exists only from Bizkaia and cannot confirm identic origins with Araba. Authors need to clarify why they considered this the same (multicentric?) outbreak.

4. Authors suspect that two miniature goats travelling on June 28 from Bizkaia to Orense were the source of infection: reception at the Bizkaia platform – Araba platform (animals did not leave the van) – central headquarters at Madrid, where animals were transferred to another vehicle. How did these two animals shed C. burnettii in Araba (even not being handled), but in Madrid, where they were transferred and handled, no humans cases were reported? Although possible this is not likely, hence I would suggest to discuss these drawbacks.

Reviewer #3: “A Q fever outbreak associated to courier transport of pets” (PONE-D-19-18129) for PLOS ONE

Reviewer’s comments

This manuscript represents a detailed account of an outbreak investigation associated with transportation of pets via a courier transport service. While it is an important study, there are considerable shortcomings related to lack of detail in the methods concerning information collected in the questionnaire, participant recruitment, the counting of cases and non-cases is recorded differently in the abstract and in results, and there is lack of clarity in some sections.

Title

The title is misleading as it indicates that the outbreak was associated with pets when in fact the source of infection was the carrying of goats – transportation of livestock/ruminants has a different risk to carrying domestic pets.

Abstract

Line 26 – I’m confused as about the term parcel distribution – this needs to be related to the delivery of pets, or is parcel distribution a different service

Line 28-29 – needs to be clear that the total number of access is 16 as you are counting probable as cases – I sound this section confusing - not sure why you are including the 7 non-cases who required medical services if not related to Q fever illness

Line 39 – needs to be clear the dust which was identified as same genotype a previous studies in that region was obtained from the pet holding site – it’s confusing the way it is written

Line 40-41 - the authors indicate that the source of the outbreak is transport of small ruminants which makes the title of the manuscript misleading unless the miniature goats are pets? – Or are they livestock/ruminants transported to farms?

Line 43 – miniature goats was the source of the outbreak yet the serology was negative – this is confusing and needs to be clarified, needs to link with the positive dust results

Line 44 – need more explanation or clarify what you mean by “Q fever was included among the occupational-associated health risks” – included in what?

Introduction

Line 51 – my understanding is that Q is not distributed worldwide – can this be checked please, a reference is also required

Line 53 - 55 – needs reference

Line 55 – what type of pets and wild species?

Line 57 – what are the animal reservoirs?

Line 64 – need to add “that” – “recent outbreaks that occurred”

Information about the incubation period is missing and should be added – this will help the reader to understand the epidemic curve and time of exposure ie. transportation of goats - to onset of illness

Material and Methods

Line 74 – is the courier company specific to pet transportation?

Line 84 – what type of urgent parcel delivery services – pets?

Line 89 – is delivery of pets to households, farms etc – need to be specific

Line 94 – what is the distance from local platform to Madrid and destination – is the route through country areas, or regions noted for livestock farming –? Possible exposure associated with windborne spread

Line 122-123 –what information was elicited from questionnaire – other risk factors or exposure information collected? How were participants recruited – eg. on-line survey, interview – this section needs more information – what was the time period

Line 124 – was the group of workers the 64 who completed the questionnaire? Please make this clearer

Line 139 – explain why the investigation was 3 weeks before – this is why you should specify the incubation period in the Introduction. What is meant by “suspect deliveries” When were the animals investigated – how long after, how were the located – had they already been delivered to their destination?

Line 144 -145 – here you should briefly how and where the environmental samples were taken

Line 155 – need to make it clear that the case definition included laboratory confirmed and probable cases, why did the authors include doubtful laboratory results?

Line 159 – here you mention personnel risk factors – but in the methods for data collection you don’t describe what information is collected - see my earlier comment on this

Results

Line 184-187 – I’m confused by the counts – in the Abstract 108 workers were exposed, yet in this section 180 workers were exposed. I’m also confused by 64 of the remaining 144 workers agreed to complete the questionnaire – where does 108 in the Abstract come from?

Line 87 – age group 6 to 20 is very large – is it possible to narrow the age group – is it more likely that cases were notified in children – this makes a difference when thinking about source of infection and risk factors

Line 88 – were the 42 cases reported during 2013 linked to an outbreak – or were they sporadic cases – outbreak cases will have a different relationship in that climate conditions may be different for those with a common exposure compared to sporadic cases with no identified source of infection

Line 90 – no mention of dust previously – see my earlier comments (line 68)

Line 94-95 – describe what is meant by “normal weather conditions”. Also state that you are referring to Table 2. Also explain wat is meant by “dust hovering”.

Line 96 – need explanation for dust hovering originated “inside” and “outside” the cities

Line 97 – state that you referring to Table 2. Also better to include the CI and not the p value

Line 234-235 – what I meant by “delivery considered of risk”

Line 262 – why is human vaccination not considered or discussed as a control measure

Discussion

Line 307 – was testing done on the flock of origin – how was trackback conducted and how many tested?

Parts of the Discussion was confusing to read and lacked clarity – eg. Line 302

I find it odd that there is mention of Q fever human vaccination as a control measure. In the last paragraph the authors discuss that a One Health approach is needed, yet there is no discussion of what One Health is and why it would be an effective approach.

Table 1

I found this table difficult to read and follow

Figure 1

Title missing for y-axis

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2019 Nov 25;14(11):e0225605. doi: 10.1371/journal.pone.0225605.r002

Author response to Decision Letter 0


18 Oct 2019

PONE-D-19-18129

A Q fever outbreak associated to courier transport of pets

PLOS ONE

Editor Comments:

I invited and received three reviews for your manuscript. All reviews raised some substantial concerns about your manuscript as it currently stands. I read through their comments and found that they coincided on several points, and that their reviews were uniformly solid and detailed. I read the manuscript myself, and I must say that I coincide with the reviewers' points entirely. As such, I would recommend “major revision”. I would kindly ask you to go through all comments raised by each reviewer and address them properly before sending a revised version of this manuscript. Please check all PLOS ONE style requirements available via https://journals.plos.org/plosone/s/submission-guidelines before submitting the revised version.

AU: Thank you for giving us the opportunity to improve the manuscript. We have done the changes and modifications suggested by the reviewers, and we have answered the comments and questions point-by-point (see below).

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

AU: We have followed the journal instructions and we think now the manuscript fits the style requirements of PLOS ONE, including file naming.

2. In your Methods, please state the volume of the blood samples collected for use in your study."

AU: In the revised manuscript we now state that tubes of 4mL were used for blood extraction (line 152).

3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts

a)If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

AU: The investigation of an outbreak is under the responsibility of the competent authority, which in this case is the Epidemiology Service of the Department of Public Health of the Basque Government. At the time of conducting the investigation of the outbreak described in this work, the written consent of the workers was requested for blood sampling and for conducting the surveys. Data derived from the questionnaires (including personal and clinical data) and the laboratory analyses results are available upon request to Eva Alonso from Public Health Department from the Basque Government (tepidebi-san@euskadi.eus).

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

Reviewer #3: No

________________________________________

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

Reviewer #3: Yes

________________________________________

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

________________________________________

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

Reviewer #3: No

________________________________________

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Although I believe that the authors have investigated the outbreak with care, I do not believe that the article has any new or illuminating insights. It is not at all surprising that an outbreak of Q fever occurred in a business that transported goats and sheep. The association of Q fever with these ruminants was established decades ago, and the ability of Coxiella burnetii to survive in dust for long periods is also well-known. The clinical features of disease in the infected patients in this study are consistent with previous reports, with no novel elements noted.

AU: Yes, we understand perfectly the reviewer’s concern regarding novelty. However, the purpose of this article is to give an insight into the need to address the importance of testing the health status of pets before transport and highlight the important but generally neglected zoonotic risks associated to Coxiella when transporting pets by courier transport companies. In addition, this article highlights the difficulty of investigating Q fever outbreaks. By the time the first cases appear and suspicion of an outbreak is considered, in the absence of normalized action protocols, decisions ought to be taken on the spot based on the the oncoming results as they are being obtained. Regarding the clinical features associated to the affected patients, it is interesting to see how in northern Spain, Q fever develops with pneumonia rather than with liver disesase as is the case in other regions. The association of this case with the MST13 genotype is another important finding. This information is also of interest since there are not many studies in Spain that relate clinical forms with genotypes.

Reviewer #2: AUTHORS

Manuscript Number: PONE-D-19-18129

Manuscript Title: A Q fever outbreak associated to courier transport of pets

This is an outbreak report of Q fever in an express transport company linked to the transport of caprine, that had epidemic characteristics. It is an interesting and valid text that has an impact on the Public Health approach of this zoonosis. However I have major concerns that need to be addressed before acceptance.

1. Line 78: “possible cases of Q fever in two workers of the Araba branch of the same company who lived in Castilla-León.” What do you mean by Bizkaia and Araba branches? Are these cities? How far apart? How is this connected to Castilla-Leon? I believe this sentence would gain if rephrased for clarification.

AU: The reviewer is right, we talk about Bizkaia, Araba and Castilla-León, without explaining that they are provinces or regions in Spain. Now in the Case Presentation section of the revised manuscript there is a brief description of the location of the regions or provinces affected (lines 76-77).

2. Line 144: “masks). Later on, on July 22, a specialized” delete “on”

AU: ‘on’ has been deleted (line 124)

3. No environmental samples were taken from Araba and no link was found between these two branches that could justify a common cause (for example, same animal provider), other than occurring on the same dates. Additionally, molecular evidence exists only from Bizkaia and cannot confirm identic origins with Araba. Authors need to clarify why they considered this the same (multicentric?) outbreak.

AU: When the Epidemiology Service learned about the outbreak (August 3), a month had passed since the first cases with Q fever symptoms, and the company had already cleaned and disinfected the premises located both in Bizkaia and Araba (22 July). When environmental sampling was carried out on September 15, 2 months after the beginning of the outbreak, sampling efforts were focused on the pet holding site and surrounding areas of the platform of Bizkaia, because clinical and serological results indicated that the origin was there. It is true that Araba's facilities should have also been sampled, but since human cases in Araba platform ocurred soon after those in Bizkaia, everything pointed to Bizkaia as source of the outbreak. Therefore, and considering the period of time that had already lapsed since the onset of the outbreak, additional samplings were not considered, and the association with the Bizkaia branch was based on epidemiological data only.

4. Authors suspect that two miniature goats travelling on June 28 from Bizkaia to Orense were the source of infection: reception at the Bizkaia platform – Araba platform (animals did not leave the van) – central headquarters at Madrid, where animals were transferred to another vehicle. How did these two animals shed C. burnettii in Araba (even not being handled), but in Madrid, where they were transferred and handled, no humans cases were reported? Although possible this is not likely, hence I would suggest to discuss these drawbacks.

AU: Yes, this is not easy to explain. One possibility, as stated in the discussion, might be that travel containers, transport vans or workers travelling from Bizkaia to Araba could have acted as vehicles for C. burnetii contamination of the Araba platform. In Madrid, since clinical symptoms compatible with Q fever were not reported by the workers, seroconversion was not assessed. In fact, no serological tests or epidemiological surveys were conducted in Madrid, and therefore infection status of the workers at Madrid was not investigated.

Reviewer #3: “A Q fever outbreak associated to courier transport of pets” (PONE-D-19-18129) for PLOS ONE

Reviewer’s comments

This manuscript represents a detailed account of an outbreak investigation associated with transportation of pets via a courier transport service. While it is an important study, there are considerable shortcomings related to lack of detail in the methods concerning information collected in the questionnaire, participant recruitment, the counting of cases and non-cases is recorded differently in the abstract and in results, and there is lack of clarity in some sections.

AU: There was a mistake in the Abstract, and instead of 108 it should say 180 workers. This has now been changed in the revised manuscript (line 28). After gathering information from the company and all the organizations involved in the service, a total of 180 workers were identified as exposed. All of them were informed of the situation and the associated risks but for the reasons explained (residence in other communities, holiday periods, or lack of time, etc.) only 64 of them agreed to take part in the epidemiological study

The questionnaire included questions related to patient, disease and occupational data, exposure risk outside the company, and personal risk associated data. The questionnaire used in the epidemiological investigation has been included in the manuscript as Supporting information (S1 Appendix) (line 136, line 449).

Title

The title is misleading as it indicates that the outbreak was associated with pets when in fact the source of infection was the carrying of goats – transportation of livestock/ruminants has a different risk to carrying domestic pets.

AU: The courier company has a Pet Transportation Service and the most important limit to provide transport service and therefore consider the animal a pet is the weight of the animal. They transport mainly dogs and cats, and eventually other pets, such as birds, rabbits, or miniature goats, like in this study. Although miniature goats are ruminants, they are most commonly kept as pets. As this Q fever outbreak took place in a transport company of these characteristics we thought it was interesting to reflect it in the title. Therfore, we would rather keep the title as it is.

Abstract

Line 26 – I’m confused as about the term parcel distribution – this needs to be related to the delivery of pets, or is parcel distribution a different service

AU: The term parcel distribution refers to the selection and distribution of the consignment according to destination. The same is done with animal cages, which have special storage places in the platforms.

Line 28-29 – needs to be clear that the total number of access is 16 as you are counting probable as cases – I sound this section confusing - not sure why you are including the 7 non-cases who required medical services if not related to Q fever illness

AU: As soon as the company suspected of the possibility of infection among the workers, they were encouraged to visit their doctor or nearest hospital in case they had any symptom (fever, pneumonia, etc ...). Seven workers that participated in the questionnaire and had compatible symptoms (including one case of pneumonia) in the outbreak period did not meet the laboratory criteria of Q fever, and they were thus considered as Non-case. To avoid misunderstandings we have deleted this information from the Abstract and further explained it in the results section (lines 210-212) and Table 1.

Line 39 – needs to be clear the dust which was identified as same genotype a previous studies in that region was obtained from the pet holding site – it’s confusing the way it is written

AU: The sentence has been rephrased (line 41-42).

Line 40-41 - the authors indicate that the source of the outbreak is transport of small ruminants which makes the title of the manuscript misleading unless the miniature goats are pets? – Or are they livestock/ruminants transported to farms?

AU: As comented above, the courier company has a Pet Transportation Service with limit on the weight of the transported animals. They transport mainly dogs and cats, and eventually other pets, which include miniature goats. Miniature goats are frequently kept as pets. As the outbreak of Q fever took place in a courier company that transports miniature goats in the same manner that conventional pets are transported, we found it interesting to reflect it in the title.

Line 43 – miniature goats was the source of the outbreak yet the serology was negative – this is confusing and needs to be clarified, needs to link with the positive dust results

AU: As explained in the manuscript, the month before the onset of the Q fever outbreak there were 2 shipments of miniature goats, but only one could be serologically investigated. Being this one negative, it is likely that the outbreak originated in the other shipment of goats that took place in mid-June. Unfortunately, this is only a hypothesis that could not be confirmed. The implication of goats in other recent outbreaks of Q fever in the Basque Country, and the fact that the genotype found in this outbreak is commonly found in goats (SNP1-MST-13), led us to think that the cause of the outbreak was the transport of miniature goats, since due to weight restriction, the company does not transport conventional goats.

In the revised manuscript, explicit reference to the miniature goats as the source of the outbreak has been deleted, and this is further explained in the body of the manuscript.

Line 44 – need more explanation or clarify what you mean by “Q fever was included among the occupational-associated health risks” – included in what?

AU: The company performs occupational health risk assessments as part of their Safety and Health Program. Before the outbreak, Q fever was not considered as an occupational health risk for the workers; after the outbreak, it has been included. This situation is further explained in the Discusion (lines 353-355, lines 369-370).

Introduction

Line 51 – my understanding is that Q is not distributed worldwide – can this be checked please, a reference is also required

AU: Q fever has worldwide distribution and it has been found in all those countries where its presence has been investigated, with the exception of New Zealand. A reference has been added to support the sentence (line 53).

Line 53 - 55 – needs reference

AU: A reference has been added (line 58)

Line 55 – what type of pets and wild species?

AU: Two new references have been added. One to indicate that C. burnetii also infects pets, such as cats and dogs. Regarding wild animals, there are many species where C. burnetii DNA has been detected and we have selected one review which compiles many studies performed in wildlife.

Line 57 – what are the animal reservoirs?

AU: Animal reservoirs are those that maintain infection active and shed C. burnetii by different routes to the environment. We have added this explanation in the new version of the manuscript (lines 60-61).

Line 64 – need to add “that” – “recent outbreaks that occurred”

AU: Added (line 67)

Information about the incubation period is missing and should be added – this will help the reader to understand the epidemic curve and time of exposure ie. transportation of goats - to onset of illness

AU: The incubation period of Q fever is between 2 and 3 weeks. This information has been added in the text (lines 128-129)

Material and Methods

Line 74 – is the courier company specific to pet transportation?

Line 84 – what type of urgent parcel delivery services – pets?

AU: It is a courier company that in addition to urgent transport of parcels it is also authorized to transports animals, the only restriction being a maximum weight of 80 kg. Animals transported are mostly dogs and cats. When transporting animals, they arrive at destination within 24 hours after collection.

Line 89 – is delivery of pets to households, farms etc – need to be specific

AU: It is not a conventional transport of farm animals; animals are individually transported between particulars. If the sender or recipient has a farm, this information is not registered by the courier company.

Line 94 – what is the distance from local platform to Madrid and destination – is the route through country areas, or regions noted for livestock farming –? Possible exposure associated with windborne spread

AU: The distance between the 2 platforms of Bizkaia and Araba is 60 km (indicated now in lines 83-84), and 361 km from the platform of Araba to Madrid (indicated now in line 245). The roads used are main highways (AP-1, A-1). The presence of farms along the route cannot be ruled out, and neither that the workers exposure had been associated with windborne spread of C. burnetii. However, the succession of clinical cases and the laboratory results, along with the epidemiological data derived from the questionnaire, suggest that exposure occurred at the platform of Bizkaia where most of the cases concentrated.

Line 122-123 –what information was elicited from questionnaire – other risk factors or exposure information collected? How were participants recruited – eg. on-line survey, interview – this section needs more information – what was the time period

AU: The translated questionnaire is now presented as supplementary data(S1 Appendix). Two on-site meetings were held, one at each platform, to inform the workers. During those meetings, blood samples were collected and workers answered the questionnaire (lines 132-137). Several workers did not attend these meetings but the Epidemiological Surveillance Unit phoned them and the workers completed the questionnaire by telephone and were asked to attend the health prevention service of the mutual insurance company to provide a blood sample for serological testing.

Line 124 – was the group of workers the 64 who completed the questionnaire? Please make this clearer.

AU: Yes, 64 workers filled the questionnaire and also gave authorization for blood extraction.

Line 139 – explain why the investigation was 3 weeks before – this is why you should specify the incubation period in the Introduction. What is meant by “suspect deliveries” When were the animals investigated – how long after, how were the located – had they already been delivered to their destination?

AU: Now in the revised manuscript the incubation period of Q fever is mentioned (lines 128-129). Taking into account the incubation period of 2 to 3 weeks and the date of onset of symptoms of the first cases, the exposure period was established from June 1 until August 8.

With the term ‘suspect deliveries’ we referred to the deliveries of ruminants that took place in this period and were therefore considered as possible source of the outbreak. There were two deliveries under suspicion but only one could be investigated at origin (August 23) and destiny (August 25), three weeks after the Epidemiological Surveillance Unit was informed of the Q fever cases. The term ‘suspect deliveries’ has been now deleted.

Line 144 -145 – here you should briefly how and where the environmental samples were taken

AU: Two aerosol samples were taken with an air sampler (Sartorius) inside the platform of Bizkaia. Dust samples were taken with cotton swabs in areas with accumulated dust in pet holding facilities and other places in the courier premises, giving a total of 19 surface dust samples analysed (lines 156-160). These samples were taken from the different surfaces indicated in Fig 2.

Line 155 – need to make it clear that the case definition included laboratory confirmed and probable cases, why did the authors include doubtful laboratory results?

AU: As indicated in the “Laboratory methods” section, “laboratory results were considered doubtful when only one blood sample was available and an indirect immunofluorescence antibody test (IFAT) titers for phase II IgG were >1/128 and for phase II IgM of >1/256.” In the context of an outbreak, the cases without symptoms but with a single positive serology are considered as probable cases so that they can be followed up to monitor a possible evolution towards chronic Q fever.

Line 159 – here you mention personnel risk factors – but in the methods for data collection you don’t describe what information is collected - see my earlier comment on this

AU: The information included in the questionnaire has been added as Supporting information (S1 Appendix) (lines 448-449).

Results

Line 184-187 – I’m confused by the counts – in the Abstract 108 workers were exposed, yet in this section 180 workers were exposed. I’m also confused by 64 of the remaining 144 workers agreed to complete the questionnaire – where does 108 in the Abstract come from?

AU: As explained above there was a mistake in the abstract. Instead of 108, the total number of workers is 180. We have modified the text (line 28).

Line 87 – age group 6 to 20 is very large – is it possible to narrow the age group – is it more likely that cases were notified in children – this makes a difference when thinking about source of infection and risk factors

AU: We think that this and the next 5 comments are not related to this manuscript (No children were investigated in this study).

Line 88– were the 42 cases reported during 2013 linked to an outbreak – or were they sporadic cases – outbreak cases will have a different relationship in that climate conditions may be different for those with a common exposure compared to sporadic cases with no identified source of infection

AU: This comment is not related to this manuscript

Line 90 – no mention of dust previously – see my earlier comments (line 68)

AU: We cannot find in the manuscript any reference to the earlier comments of the reviewer

Line 94-95 – describe what is meant by “normal weather conditions”. Also state that you are referring to Table 2. Also explain wat is meant by “dust hovering”.

AU: Table 2 does not exist. We do not mention in the manuscript the terms “normal weather conditions” or “dust hovering”.

Line 96 – need explanation for dust hovering originated “inside” and “outside” the cities

AU: This sentence does not appear in the text

Line 97 – state that you referring to Table 2. Also better to include the CI and not the p value

AU: Table 2 does not exist

Line 234-235 – what I meant by “delivery considered of risk”

AU: This has been rephrased (lines 241-242, 251)

Line 262 – why is human vaccination not considered or discussed as a control measure

AU: Human vaccination has been used in Australia in groups of risk. This vaccine can induce local reactions, and patients should be evaluated with a cutaneous test for Q fever before vaccination to avoid severe side effects. At present, the use of this vaccine in humans has not been considered in Spain.

Discussion

Line 307 – was testing done on the flock of origin – how was trackback conducted and how many tested?

AU: The flock of origin had 5 miniature goats and 7 sheep. All animals were analysed by ELISA test giving negative results (lines 248-249).

Parts of the Discussion was confusing to read and lacked clarity – eg. Line 302

AU: This paragraph has been modified according the comments of the reviewer and we think now this part of the discussion is clear (lines 313-315).

I find it odd that there is mention of Q fever human vaccination as a control measure. In the last paragraph the authors discuss that a One Health approach is needed, yet there is no discussion of what One Health is and why it would be an effective approach.

AU: As stated above, the use of this vaccine in humans has not been considered in our country, which is considered a Q fever endemic area. The Australian vaccine, Q-VAX, is a whole-cell reactogenic vaccine that causes severe local and general reactions in persons who have been exposed to C. burnetii before. Negative serology, followed by negative skin testing is necessary before vaccination to avoid severe reactions. This vaccine is used for risk groups in Australia but it is not licensed or used in any other countries.The study of Q fever outbreaks is a clear example of teamwork in which public health, animal health and environmental health experts team together to establish a protocol of investigation, identify the source of infection and implement control measures to avoid risk for human population (lines 363-366).

Table 1

I found this table difficult to read and follow

AU: We have suppressed one column, in order to make the read of data easier.

Figure 1

Title missing for y-axis

AU: Yes, it is true. When Power Point file was transformed in a ‘tif’ format, the title of y-axis was missed. Now, in the new versión the tittle appear as ‘no. cases’

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Abdallah M Samy

8 Nov 2019

A Q fever outbreak associated to courier transport of pets

PONE-D-19-18129R1

Dear Dr. García-Pérez,

We are pleased to inform you that your manuscript, "A Q fever outbreak associated to courier transport of pets" (PONE-D-19-18129R1), has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Abdallah M. Samy, PhD

Academic Editor

PLOS ONE

Acceptance letter

Abdallah M Samy

13 Nov 2019

PONE-D-19-18129R1

A Q fever outbreak associated to courier transport of pets

Dear Dr. García-Pérez:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Abdallah M. Samy

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Appendix. Questionnaire used in the epidemiological investigation.

    (DOCX)

    S1 Table. Serological data compiled from workers.

    (XLSX)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files. However, under the Data Protection laws, raw individual personal and clinical data extracted from the questionnaires cannot be provided since they represent sensitive information. However, any request for additional information will be considered and provided upon request to the Epidemiology Service of the Department of Public Health of the Basque Government (e-mail: epidemiologia-bizkaia@euskadi.eus).


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES